Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.974 EUR | -0.32% | -3.88% | +36.12% |
05-07 | AstraZeneca target raised; Antofagasta lowered | AN |
05-03 | AIB GROUP : Stronger revenue growth and a benign cost of risk |
Sales 2024 * | 4.56B 4.91B 385B | Sales 2025 * | 4.34B 4.67B 367B | Capitalization | 12.34B 13.29B 1,044B |
---|---|---|---|---|---|
Net income 2024 * | 1.76B 1.9B 149B | Net income 2025 * | 1.56B 1.68B 132B | EV / Sales 2024 * | 2.71 x |
Net cash position 2024 * | - 0 0 | Net cash position 2025 * | - 0 0 | EV / Sales 2025 * | 2.84 x |
P/E ratio 2024 * |
7.11
x | P/E ratio 2025 * |
7.4
x | Employees | 10,551 |
Yield 2024 * |
5.89% | Yield 2025 * |
6.25% | Free-Float | 68.01% |
Latest transcript on AIB Group plc
1 day | -0.32% | ||
1 week | -3.88% | ||
Current month | -7.03% | ||
1 month | +1.47% | ||
3 months | +15.46% | ||
6 months | +29.46% | ||
Current year | +36.12% |
Managers | Title | Age | Since |
---|---|---|---|
Colin Hunt
CEO | Chief Executive Officer | 54 | 31/12/15 |
Donal Galvin
DFI | Director of Finance/CFO | 50 | 31/08/13 |
Graham Fagan
CTO | Chief Tech/Sci/R&D Officer | - | 18/10/23 |
Members of the board | Title | Age | Since |
---|---|---|---|
Fergal O’Dwyer
BRD | Director/Board Member | 64 | 21/01/21 |
James Pettigrew
CHM | Chairman | 65 | 27/10/21 |
Brendan McDonagh
BRD | Director/Board Member | 66 | 26/10/16 |
Date | Price | Change | Volume |
---|---|---|---|
10/06/24 | 4.974 | -0.32% | 0 |
07/06/24 | 4.99 | +0.20% | 0 |
06/06/24 | 4.98 | -0.80% | 0 |
05/06/24 | 5.02 | -2.43% | 0 |
04/06/24 | 5.145 | -0.58% | 0 |
Delayed Quote Deutsche Boerse AG, June 10, 2024 at 08:19 am
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+17.35% | 574B | |
+17.82% | 311B | |
+13.87% | 254B | |
+19.35% | 184B | |
+24.83% | 172B | |
+9.14% | 163B | |
+9.11% | 150B | |
-8.66% | 143B | |
+10.95% | 138B |
- Stock Market
- Equities
- A5G Stock
- A5G Stock